pharmaphorum | News & views on pharma and biotech’s evolving …
网页pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future.
J&J nets another key approval for blockbuster hope Rybrevant
网页1 天前 · J&J's high expectations for Rybrevant are driven mainly by its August approval with Lazcluze, which outperformed Tagrisso in the head-to-head MARIPOSA study, but second-line use will be an ...
Sanofi's tolebrutinib cuts MS progression by 31% in trial
网页1 天前 · Roche trumpets new fenebrutinib data in relapsing MS. Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability ...
Supply chain resilience in pharma: Delivering consistency amidst …
网页2 天之前 · Resilience across every facet of the pharmaceutical supply chain is paramount, whether ecological, societal, organisational, or psychological. This requires adaptability in pressured situations ...
Increasing sustainability in pharma requires an industry-wide effort
网页3 天之前 · After FDA no, MSD/Daiichi post new data with lung cancer ADC. MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as ...
Lilly’s Mounjaro wins latest head-to-head battle in clinical trials of ...
网页3 天之前 · Diabetes is one of the most common health conditions in the United States, afflicting more than 11% of the population, with over 90% included in the type 2 category. Mounjaro, manufactured by ...
pharmaphorum - The Deep Dive Digital Magazine has fresh …
网页2024年2月28日 · Digital Health 2023. 29-11-2023 Deep Dive – Digital Health 2023 features interviews, analysis, and commentary from pharmaphorum, Lumanity, AXON, Viseven, Research Partnership, PurpleLeaf Strategy, M3, and more
News | Timely industry updates for pharma and biotech leaders
网页LEAP HR: Emerging Biopharma. pharmaphorum’s news coverage updates daily with the latest pharma and biotech stories, from funding and M&A to regulatory approvals and policy shifts.
AstraZeneca takes on CVRM - pharmaphorum
网页Research and Development Disruption 2020 | AstraZeneca takes on CVRM. One of Pascal Soriot’s first big decisions after taking over as CEO of AstraZeneca was to take control of a long-standing diabetes alliance with Bristol-Myers Squibb. The deal signed in 2014 gave AZ full control over what is turning out to be one of its most important drugs ...
TauRx sees path to FDA filing for tau-targeting Alzheimer's drug
网页3 天之前 · TauRx was an early proponent of the notion that tau protein could be a legitimate drug target in Alzheimer's, since it was taken up by a lot of larger companies, including Roche/UCB, Johnson ...